The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
In a small trial, patients receiving 300 U and 500 U of intravesical abobotulinumtoxin A experienced reductions in nocturia episodes at 12 and 24 weeks.
Recent studies provide insight into the epidemiology of the condition and its associated complications.
